Statements (95)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Onyx_Pharmaceuticals
|
| gptkbp:activities |
proteasome inhibitor
|
| gptkbp:affects |
not fully known
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:2012
gptkb:FDA gptkb:United_States requires sterile water |
| gptkbp:availability |
prescription only
|
| gptkbp:can_be_used_with |
gptkb:bortezomib
gptkb:lenalidomide gptkb:dexamethasone |
| gptkbp:class |
antineoplastic agent
immunomodulator |
| gptkbp:clinical_trial |
gptkb:healthcare_organization
Phase 1 Phase 2 Phase 3 treatment of cancer ongoing studies published in medical journals |
| gptkbp:contraindication |
hypersensitivity to carfilzomib
severe heart problems |
| gptkbp:current_use |
gptkb:refractory_multiple_myeloma
relapsed multiple myeloma plasma cell leukemia |
| gptkbp:dosage_form |
gptkb:software_framework
weekly administration |
| gptkbp:education |
provided by healthcare providers
|
| gptkbp:effective_date |
gptkb:2012
|
| gptkbp:excretion |
biliary and fecal
|
| gptkbp:formulation |
lyophilized powder
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kyprolis
|
| gptkbp:indication |
gptkb:relapsed_or_refractory_multiple_myeloma
|
| gptkbp:ingredients |
gptkb:carfilzomib
C22 H29 N3 O5 S |
| gptkbp:interacts_with |
live vaccines
other chemotherapy agents CY P450 inducers CY P450 inhibitors caution with other myelosuppressive agents |
| gptkbp:invention |
patented
|
| gptkbp:is_atype_of |
L01 X X32
|
| gptkbp:is_effective_against |
improves survival rates
reduces disease progression |
| gptkbp:is_monitored_by |
cardiac function
kidney function liver function blood cell counts blood counts |
| gptkbp:is_used_for |
gptkb:healthcare_organization
|
| gptkbp:lifespan |
approximately 30 minutes
|
| gptkbp:manager |
intravenous
IV infusion |
| gptkbp:manufacturer |
gptkb:Amgen
|
| gptkbp:marketed_as |
gptkb:brand
many countries Kyprolis for Injection |
| gptkbp:metabolism |
primarily hepatic
|
| gptkbp:packaging |
single-use vial
|
| gptkbp:pharmacokinetics |
rapidly distributed
|
| gptkbp:population |
adults
|
| gptkbp:price |
varies by region
|
| gptkbp:provides_information_on |
ASCO guidelines
included in treatment protocols NCCN guidelines |
| gptkbp:receives_funding_from |
supported by grants
|
| gptkbp:requires |
available online
|
| gptkbp:research_and_development |
ongoing
|
| gptkbp:research_focus |
combination therapies
biomarker studies long-term outcomes resistance mechanisms quality of life studies |
| gptkbp:safety_features |
well-studied
|
| gptkbp:scholarships |
available for eligible patients
available through manufacturer |
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
gptkb:fandom
fatigue nausea diarrhea heart failure pulmonary hypertension thrombocytopenia infection risk neuropathy neutropenia kidney toxicity cardiac toxicity |
| gptkbp:storage |
room temperature
refrigerated |
| gptkbp:type_of |
868540-17-4
|